Get a head start on one of the biggest heart failure conferences of the year with our HFSA 2026 preview.

In a phase 3 study, telikibart achieved EASI-75 in 69.6% of adult patients with atopic dermatitis at Week 16, with rates above 94% by Week 52.

An indirect comparison finds higher placebo-adjusted skin and itch responses with upadacitinib vs nemolizumab in atopic dermatitis.

Check out highlights from news published on Day 3 of the EADV Congress 2026, spanning psoriasis, cutaneous lupus, atopic dermatitis, and more.

Werth discusses what the 52-week AMETHYST Part A data add to the case for litifilimab in antimalarial-refractory cutaneous lupus erythematosus.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.

Oral icotrokinra sustained clearance at scalp, genital, hand/foot, and nail sites through Week 112 in ICONIC-TOTAL, with no rise in adverse event rates.

Stay up-to-date with the latest FDA approvals, trial readouts, and key clinician insights across cardiovascular care.